Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets

Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) w...

Full description

Bibliographic Details
Main Author: R. O. Dreval
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2018-06-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/826